Human miRNAs to Identify Potential Regions of SARS-CoV-2

ACS Omega. 2022 Jun 7;7(24):21086-21101. doi: 10.1021/acsomega.2c01907. eCollection 2022 Jun 21.

Abstract

It is two years now but the world is still struggling against COVID-19 due to the havoc created by the SARS-CoV-2 virus and its multiple variants. Considering this perspective, in this work, we have hypothesized a new approach in order to identify potential regions in SARS-CoV-2 similar to the human miRNAs. Thus, they may have similar consequences as caused by the human miRNAs in human body. Therefore, the same way by which human miRNAs are inhibited can be applied for such potential regions of virus as well by administering drugs to the interacting human proteins. In this regard, the multiple sequence alignment technique Clustal Omega is used to align 2656 human miRNAs with the SARS-CoV-2 reference genome to identify the potential regions within the virus reference genome which have high similarities with the human miRNAs. The potential regions in virus genome are identified based on the highest number of nucleotide match, greater than or equal to 5 at a genomic position, for the aligned miRNAs. As a result, 38 potential SARS-CoV-2 regions are identified consisting of 249 human miRNAs. Among these 38 potential regions, some top regions belong to nucleocapsid, RdRp, helicase, and ORF8. To understand the biological significance of these potential regions, the targets of the human miRNAs are considered for KEGG pathways and protein-protein and drug-protein interaction analysis as the human miRNAs are similar to the potential regions of SARS-CoV-2. Significant pathways are found which lead to comorbidities. Subsequently, drugs like emodin, bicalutamide, vorinostat, etc. are identified that may be used for clinical trials.